Janssen Vaccines & Prevention B.V.

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

9 Countries active

3 Unique IMPs

100% Results reported

Phase III

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Escherichia urinary tract infection 1

Top IMPs

ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75 2 B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) 1 SODIUM CHLORIDE 1

All trials

2 total

A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr… Ended

2023-504168-40-00 Phase III 2 countries B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), A/VICTORIA/2570/2…
A study to evaluate ExPEC9V vaccine for the prevention of Invasive E. coli Disease in adults aged 60 years and older with a history of urina… Ended

2023-506589-30-00 Phase III 7 countries ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75

Showing 1–2 of 2 trials

← All sponsors A–Z